V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
C
CAPRAI Stock Diagnostic Report

Oppenheimer reiterates Capricor stock rating ahead of trial data

Ahead of the clinical data announcement, Oppenheimer reaffirmed its investment rating on Capricor, but with limited new catalysts, the stock’s direction is viewed as neutral.

View Source Article ↗
AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

CAPR Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-02 14:17:50CAPR40RowView Report →
2026-09-30 01:31:54CAPR80MidView Report →
2026-09-17 15:18:41CAPR45MidView Report →
View Full History for CAPR (Blueprint) →